Sarepta Therapeutics Inc. (NASDAQ:SRPT)‘s stock had its “buy” rating reissued by analysts at Needham & Company LLC in a research report issued on Saturday. They currently have a $81.00 price target on the stock. Needham & Company LLC’s price target indicates a potential upside of 39.92% from the company’s current price.
SRPT has been the subject of a number of other reports. Leerink Swann raised shares of Sarepta Therapeutics from an “underperform” rating to a “market perform” rating and set a $50.00 price objective for the company in a research note on Monday, September 19th. Piper Jaffray Cos. raised shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating in a research note on Monday, September 19th. Janney Montgomery Scott set a $30.00 price objective on shares of Sarepta Therapeutics and gave the stock a “hold” rating in a research note on Wednesday, August 3rd. William Blair raised shares of Sarepta Therapeutics from a “market perform” rating to an “outperform” rating and set a $88.00 price objective for the company in a research note on Monday, September 19th. Finally, Wedbush restated an “outperform” rating and issued a $36.00 target price on shares of Sarepta Therapeutics in a report on Tuesday, July 19th. One research analyst has rated the stock with a sell rating, five have issued a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $58.12.
Sarepta Therapeutics (NASDAQ:SRPT) opened at 57.89 on Friday. The stock’s market cap is $2.77 billion. The company’s 50 day moving average is $40.98 and its 200 day moving average is $25.39. Sarepta Therapeutics has a 12 month low of $8.00 and a 12 month high of $63.73.
Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Tuesday, July 19th. The company reported ($1.35) EPS for the quarter, missing analysts’ consensus estimates of ($1.19) by $0.16. During the same period last year, the firm earned ($0.87) EPS. On average, analysts anticipate that Sarepta Therapeutics will post ($4.23) EPS for the current fiscal year.
In other news, VP Jayant Aphale sold 35,000 shares of Sarepta Therapeutics stock in a transaction that occurred on Monday, September 19th. The shares were sold at an average price of $50.00, for a total value of $1,750,000.00. Following the transaction, the vice president now owns 21,490 shares of the company’s stock, valued at approximately $1,074,500. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Edward M. Md Kaye sold 24,557 shares of Sarepta Therapeutics stock in a transaction that occurred on Wednesday, September 14th. The stock was sold at an average price of $30.00, for a total transaction of $736,710.00. Following the completion of the transaction, the chief executive officer now directly owns 76,983 shares in the company, valued at approximately $2,309,490. The disclosure for this sale can be found here. 10.90% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently modified their holdings of the company. Teacher Retirement System of Texas increased its position in shares of Sarepta Therapeutics by 13.6% in the second quarter. Teacher Retirement System of Texas now owns 6,034 shares of the company’s stock worth $115,000 after buying an additional 724 shares during the last quarter. Advisor Group Inc. bought a new stake in Sarepta Therapeutics during the second quarter valued at $154,000. Quantitative Systematic Strategies LLC bought a new stake in Sarepta Therapeutics during the second quarter valued at $211,000. BNP Paribas Arbitrage SA increased its stake in Sarepta Therapeutics by 114.0% in the third quarter. BNP Paribas Arbitrage SA now owns 3,541 shares of the company’s stock valued at $217,000 after buying an additional 1,886 shares in the last quarter. Finally, National Planning Corp increased its stake in Sarepta Therapeutics by 2.1% in the first quarter. National Planning Corp now owns 13,678 shares of the company’s stock valued at $242,000 after buying an additional 275 shares in the last quarter. 65.29% of the stock is currently owned by hedge funds and other institutional investors.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.